APO Research
Talk to an analyst

APO RESEARCH · REPORT

Immune Mediated Tumor Killing Assays Service

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Immune Mediated Tumor Killing Assays Service Market Outlook and Growth Opportunities 2026

3 July 2026207 pages

Choose your research edition.

Industry ResearchImmune Mediated Tumor Killing Assays Service Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Immune Mediated Tumor Killing Assays Service Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Immune Mediated Tumor Killing Assays Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Immune Mediated Tumor Killing Assays Service Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Immune Mediated Tumor Killing Assays Service Market Analysis and Forecast 2026-2032181 pages · $4,950 USD

Market perspective

The global Immune Mediated Tumor Killing Assays Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Immune Mediated Tumor Killing Assays Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Immune Mediated Tumor Killing Assays Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Immune Mediated Tumor Killing Assays Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Immune Mediated Tumor Killing Assays Service market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Immune Mediated Tumor Killing Assays Service market include Agilent, Laboratories, Explicyte, Reaction Biology, Axion BioSystems, Sartorius, ICE Bioscience, Shanghai Saily Biotechnology and ProBio, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Immune Mediated Tumor Killing Assays Service market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Immune Mediated Tumor Killing Assays Service and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Immune Mediated Tumor Killing Assays Service revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Immune Mediated Tumor Killing Assays Service market.

Immune Mediated Tumor Killing Assays Service Segment by Company

Agilent

Laboratories

Explicyte

Reaction Biology

Axion BioSystems

Sartorius

ICE Bioscience

Shanghai Saily Biotechnology

ProBio

Charles River

Imodels

Xeno Diagnostics

Cyagen

MarinBio

Pharmalegacy

Celentyx

Crown Bioscience

Cellomatics Biosciences

Immune Mediated Tumor Killing Assays Service Segment by Type

Cytotoxic T Cell Assay

Natural Killer (NK) Cell Assay

Other

Immune Mediated Tumor Killing Assays Service Segment by Application

Cancer Research

Infectious Disease Research

Immunotherapy Development

Immune Mediated Tumor Killing Assays Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Immune Mediated Tumor Killing Assays Service status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Immune Mediated Tumor Killing Assays Service key companies, revenue, market share, and recent developments.

3. To split the Immune Mediated Tumor Killing Assays Service breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Immune Mediated Tumor Killing Assays Service market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Immune Mediated Tumor Killing Assays Service significant trends, drivers, influence factors in global and regions.

6. To analyze Immune Mediated Tumor Killing Assays Service competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immune Mediated Tumor Killing Assays Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Immune Mediated Tumor Killing Assays Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immune Mediated Tumor Killing Assays Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Immune Mediated Tumor Killing Assays Service industry.

Chapter 3: Detailed analysis of Immune Mediated Tumor Killing Assays Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Immune Mediated Tumor Killing Assays Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Immune Mediated Tumor Killing Assays Service in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Immune Mediated Tumor Killing Assays Service Industry Trends Table 2. Immune Mediated Tumor Killing Assays Service Industry Drivers Table 3. Immune Mediated Tumor Killing Assays Service Industry Opportunities and Challenges Table 4. Immune Mediated Tumor Killing Assays Service Industry Restraints Table 5. Global Immune Mediated Tumor Killing Assays Service Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Immune Mediated Tumor Killing Assays Service Revenue Share by Company (2021-2026) Table 7. Global Immune Mediated Tumor Killing Assays Service Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Immune Mediated Tumor Killing Assays Service Key Company Manufacturing Base & Headquarters Table 9. Global Immune Mediated Tumor Killing Assays Service Company, Product Type & Application Table 10. Global Immune Mediated Tumor Killing Assays Service Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Immune Mediated Tumor Killing Assays Service by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Cytotoxic T Cell Assay Table 15. Significant Companies of Natural Killer (NK) Cell Assay Table 16. Significant Companies of Other Table 17. Global Immune Mediated Tumor Killing Assays Service Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Immune Mediated Tumor Killing Assays Service Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Immune Mediated Tumor Killing Assays Service Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Immune Mediated Tumor Killing Assays Service Sales Value Share by Type (2021-2026) Table 21. Global Immune Mediated Tumor Killing Assays Service Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Cancer Research Table 23. Significant Companies of Infectious Disease Research Table 24. Significant Companies of Immunotherapy Development Table 25. Global Immune Mediated Tumor Killing Assays Service Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Immune Mediated Tumor Killing Assays Service Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Immune Mediated Tumor Killing Assays Service Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Immune Mediated Tumor Killing Assays Service Sales Value Share by Application (2021-2026) Table 29. Global Immune Mediated Tumor Killing Assays Service Sales Value Share by Application (2027-2032) Table 30. Global Immune Mediated Tumor Killing Assays Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Immune Mediated Tumor Killing Assays Service Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Immune Mediated Tumor Killing Assays Service Sales Value Share by Region (2021-2026) Table 33. Global Immune Mediated Tumor Killing Assays Service Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Immune Mediated Tumor Killing Assays Service Sales Value Share by Region (2027-2032) Table 35. Global Immune Mediated Tumor Killing Assays Service Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Immune Mediated Tumor Killing Assays Service Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Immune Mediated Tumor Killing Assays Service Sales Value Market Share by Country (2021-2026) Table 38. Global Immune Mediated Tumor Killing Assays Service Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Immune Mediated Tumor Killing Assays Service Sales Value Market Share by Country (2027-2032) Table 40. Agilent Company Information Table 41. Agilent Business Overview Table 42. Agilent Immune Mediated Tumor Killing Assays Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Agilent Immune Mediated Tumor Killing Assays Service Product Portfolio Table 44. Agilent Recent Development Table 45. Laboratories Company Information Table 46. Laboratories Business Overview Table 47. Laboratories Immune Mediated Tumor Killing Assays Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Laboratories Immune Mediated Tumor Killing Assays Service Product Portfolio Table 49. Laboratories Recent Development Table 50. Explicyte Company Information Table 51. Explicyte Business Overview Table 52. Explicyte Immune Mediated Tumor Killing Assays Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Explicyte Immune Mediated Tumor Killing Assays Service Product Portfolio Table 54. Explicyte Recent Development Table 55. Reaction Biology Company Information Table 56. Reaction Biology Business Overview Table 57. Reaction Biology Immune Mediated Tumor Killing Assays Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Reaction Biology Immune Mediated Tumor Killing Assays Service Product Portfolio Table 59. Reaction Biology Recent Development Table 60. Axion BioSystems Company Information Table 61. Axion BioSystems Business Overview Table 62. Axion BioSystems Immune Mediated Tumor Killing Assays Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Axion BioSystems Immune Mediated Tumor Killing Assays Service Product Portfolio Table 64. Axion BioSystems Recent Development Table 65. Sartorius Company Information Table 66. Sartorius Business Overview Table 67. Sartorius Immune Mediated Tumor Killing Assays Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Sartorius Immune Mediated Tumor Killing Assays Service Product Portfolio Table 69. Sartorius Recent Development Table 70. ICE Bioscience Company Information Table 71. ICE Bioscience Business Overview Table 72. ICE Bioscience Immune Mediated Tumor Killing Assays Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. ICE Bioscience Immune Mediated Tumor Killing Assays Service Product Portfolio Table 74. ICE Bioscience Recent Development Table 75. Shanghai Saily Biotechnology Company Information Table 76. Shanghai Saily Biotechnology Business Overview Table 77. Shanghai Saily Biotechnology Immune Mediated Tumor Killing Assays Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Shanghai Saily Biotechnology Immune Mediated Tumor Killing Assays Service Product Portfolio Table 79. Shanghai Saily Biotechnology Recent Development Table 80. ProBio Company Information Table 81. ProBio Business Overview Table 82. ProBio Immune Mediated Tumor Killing Assays Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. ProBio Immune Mediated Tumor Killing Assays Service Product Portfolio Table 84. ProBio Recent Development Table 85. Charles River Company Information Table 86. Charles River Business Overview Table 87. Charles River Immune Mediated Tumor Killing Assays Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Charles River Immune Mediated Tumor Killing Assays Service Product Portfolio Table 89. Charles River Recent Development Table 90. Imodels Company Information Table 91. Imodels Business Overview Table 92. Imodels Immune Mediated Tumor Killing Assays Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Imodels Immune Mediated Tumor Killing Assays Service Product Portfolio Table 94. Imodels Recent Development Table 95. Xeno Diagnostics Company Information Table 96. Xeno Diagnostics Business Overview Table 97. Xeno Diagnostics Immune Mediated Tumor Killing Assays Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Xeno Diagnostics Immune Mediated Tumor Killing Assays Service Product Portfolio Table 99. Xeno Diagnostics Recent Development Table 100. Cyagen Company Information Table 101. Cyagen Business Overview Table 102. Cyagen Immune Mediated Tumor Killing Assays Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Cyagen Immune Mediated Tumor Killing Assays Service Product Portfolio Table 104. Cyagen Recent Development Table 105. MarinBio Company Information Table 106. MarinBio Business Overview Table 107. MarinBio Immune Mediated Tumor Killing Assays Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. MarinBio Immune Mediated Tumor Killing Assays Service Product Portfolio Table 109. MarinBio Recent Development Table 110. Pharmalegacy Company Information Table 111. Pharmalegacy Business Overview Table 112. Pharmalegacy Immune Mediated Tumor Killing Assays Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. Pharmalegacy Immune Mediated Tumor Killing Assays Service Product Portfolio Table 114. Pharmalegacy Recent Development Table 115. Celentyx Company Information Table 116. Celentyx Business Overview Table 117. Celentyx Immune Mediated Tumor Killing Assays Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. Celentyx Immune Mediated Tumor Killing Assays Service Product Portfolio Table 119. Celentyx Recent Development Table 120. Crown Bioscience Company Information Table 121. Crown Bioscience Business Overview Table 122. Crown Bioscience Immune Mediated Tumor Killing Assays Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 123. Crown Bioscience Immune Mediated Tumor Killing Assays Service Product Portfolio Table 124. Crown Bioscience Recent Development Table 125. Cellomatics Biosciences Company Information Table 126. Cellomatics Biosciences Business Overview Table 127. Cellomatics Biosciences Immune Mediated Tumor Killing Assays Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 128. Cellomatics Biosciences Immune Mediated Tumor Killing Assays Service Product Portfolio Table 129. Cellomatics Biosciences Recent Development Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Immune Mediated Tumor Killing Assays Service Product Image Figure 2. Global Immune Mediated Tumor Killing Assays Service Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Immune Mediated Tumor Killing Assays Service Market Size (2021-2032) & (US$ Million) Figure 4. Global Immune Mediated Tumor Killing Assays Service Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Cytotoxic T Cell Assay Image Figure 8. Natural Killer (NK) Cell Assay Image Figure 9. Other Image Figure 10. Global Immune Mediated Tumor Killing Assays Service Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Immune Mediated Tumor Killing Assays Service Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Immune Mediated Tumor Killing Assays Service Sales Value Share by Type (2021-2032) Figure 13. Cancer Research Image Figure 14. Infectious Disease Research Image Figure 15. Immunotherapy Development Image Figure 16. Global Immune Mediated Tumor Killing Assays Service Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Immune Mediated Tumor Killing Assays Service Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Immune Mediated Tumor Killing Assays Service Sales Value Share by Application (2021-2032) Figure 19. Global Immune Mediated Tumor Killing Assays Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Immune Mediated Tumor Killing Assays Service Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Immune Mediated Tumor Killing Assays Service Sales Value (2021-2032) & (US$ Million) Figure 22. North America Immune Mediated Tumor Killing Assays Service Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Immune Mediated Tumor Killing Assays Service Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Immune Mediated Tumor Killing Assays Service Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Immune Mediated Tumor Killing Assays Service Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Immune Mediated Tumor Killing Assays Service Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Immune Mediated Tumor Killing Assays Service Sales Value (2021-2032) & (US$ Million) Figure 28. South America Immune Mediated Tumor Killing Assays Service Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Immune Mediated Tumor Killing Assays Service Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Immune Mediated Tumor Killing Assays Service Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Cytotoxic T Cell Assay
  • Natural Killer (NK) Cell Assay
  • Other
Applications
  • Cancer Research
  • Infectious Disease Research
  • Immunotherapy Development
Companies covered
  • Agilent
  • Laboratories
  • Explicyte
  • Reaction Biology
  • Axion BioSystems
  • Sartorius
  • ICE Bioscience
  • Shanghai Saily Biotechnology
  • ProBio
  • Charles River
  • Imodels
  • Xeno Diagnostics
  • Cyagen
  • MarinBio
  • Pharmalegacy
  • Celentyx
  • Crown Bioscience
  • Cellomatics Biosciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Immune Mediated Tumor Killing Assays Service Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Immune Mediated Tumor Killing Assays Service Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Immune Mediated Tumor Killing Assays Service Market Dynamics
  1. 2.1 Immune Mediated Tumor Killing Assays Service Industry Trends
  2. 2.2 Immune Mediated Tumor Killing Assays Service Industry Drivers
  3. 2.3 Immune Mediated Tumor Killing Assays Service Industry Opportunities and Challenges
  4. 2.4 Immune Mediated Tumor Killing Assays Service Industry Restraints
3 Immune Mediated Tumor Killing Assays Service Market by Company
  1. 3.1 Global Immune Mediated Tumor Killing Assays Service Company Revenue Ranking in 2025
  2. 3.2 Global Immune Mediated Tumor Killing Assays Service Revenue by Company (2021-2026)
  3. 3.3 Global Immune Mediated Tumor Killing Assays Service Company Ranking (2024-2026)
  4. 3.4 Global Immune Mediated Tumor Killing Assays Service Company Manufacturing Base and Headquarters
  5. 3.5 Global Immune Mediated Tumor Killing Assays Service Company Product Type and Application
  6. 3.6 Global Immune Mediated Tumor Killing Assays Service Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Immune Mediated Tumor Killing Assays Service Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Immune Mediated Tumor Killing Assays Service Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Immune Mediated Tumor Killing Assays Service Market by Type
  1. 4.1 Immune Mediated Tumor Killing Assays Service Type Introduction
  2. 4.1.1 Cytotoxic T Cell Assay
  3. 4.1.2 Natural Killer (NK) Cell Assay
  4. 4.1.3 Other
  5. 4.2 Global Immune Mediated Tumor Killing Assays Service Sales Value by Type
  6. 4.2.1 Global Immune Mediated Tumor Killing Assays Service Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Immune Mediated Tumor Killing Assays Service Sales Value by Type (2021-2032)
  8. 4.2.3 Global Immune Mediated Tumor Killing Assays Service Sales Value Share by Type (2021-2032)
5 Immune Mediated Tumor Killing Assays Service Market by Application
  1. 5.1 Immune Mediated Tumor Killing Assays Service Application Introduction
  2. 5.1.1 Cancer Research
  3. 5.1.2 Infectious Disease Research
  4. 5.1.3 Immunotherapy Development
  5. 5.2 Global Immune Mediated Tumor Killing Assays Service Sales Value by Application
  6. 5.2.1 Global Immune Mediated Tumor Killing Assays Service Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Immune Mediated Tumor Killing Assays Service Sales Value by Application (2021-2032)
  8. 5.2.3 Global Immune Mediated Tumor Killing Assays Service Sales Value Share by Application (2021-2032)
6 Immune Mediated Tumor Killing Assays Service Regional Value Analysis
  1. 6.1 Global Immune Mediated Tumor Killing Assays Service Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Immune Mediated Tumor Killing Assays Service Sales Value by Region (2021-2032)
  3. 6.2.1 Global Immune Mediated Tumor Killing Assays Service Sales Value by Region: 2021-2026
  4. 6.2.2 Global Immune Mediated Tumor Killing Assays Service Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Immune Mediated Tumor Killing Assays Service Sales Value (2021-2032)
  7. 6.3.2 North America Immune Mediated Tumor Killing Assays Service Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Immune Mediated Tumor Killing Assays Service Sales Value (2021-2032)
  10. 6.4.2 Europe Immune Mediated Tumor Killing Assays Service Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Immune Mediated Tumor Killing Assays Service Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Immune Mediated Tumor Killing Assays Service Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Immune Mediated Tumor Killing Assays Service Sales Value (2021-2032)
  16. 6.6.2 South America Immune Mediated Tumor Killing Assays Service Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Immune Mediated Tumor Killing Assays Service Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Immune Mediated Tumor Killing Assays Service Sales Value Share by Country, 2025 VS 2032
7 Immune Mediated Tumor Killing Assays Service Country-level Value Analysis
  1. 7.1 Global Immune Mediated Tumor Killing Assays Service Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Immune Mediated Tumor Killing Assays Service Sales Value by Country (2021-2032)
  3. 7.2.1 Global Immune Mediated Tumor Killing Assays Service Sales Value by Country (2021-2026)
  4. 7.2.2 Global Immune Mediated Tumor Killing Assays Service Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Immune Mediated Tumor Killing Assays Service Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Immune Mediated Tumor Killing Assays Service Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Immune Mediated Tumor Killing Assays Service Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Agilent
  2. 8.1.1 Agilent Company Information
  3. 8.1.2 Agilent Business Overview
  4. 8.1.3 Agilent Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Agilent Immune Mediated Tumor Killing Assays Service Product Portfolio
  6. 8.1.5 Agilent Recent Developments
  7. 8.2 Laboratories
  8. 8.2.1 Laboratories Company Information
  9. 8.2.2 Laboratories Business Overview
  10. 8.2.3 Laboratories Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Laboratories Immune Mediated Tumor Killing Assays Service Product Portfolio
  12. 8.2.5 Laboratories Recent Developments
  13. 8.3 Explicyte
  14. 8.3.1 Explicyte Company Information
  15. 8.3.2 Explicyte Business Overview
  16. 8.3.3 Explicyte Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Explicyte Immune Mediated Tumor Killing Assays Service Product Portfolio
  18. 8.3.5 Explicyte Recent Developments
  19. 8.4 Reaction Biology
  20. 8.4.1 Reaction Biology Company Information
  21. 8.4.2 Reaction Biology Business Overview
  22. 8.4.3 Reaction Biology Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Reaction Biology Immune Mediated Tumor Killing Assays Service Product Portfolio
  24. 8.4.5 Reaction Biology Recent Developments
  25. 8.5 Axion BioSystems
  26. 8.5.1 Axion BioSystems Company Information
  27. 8.5.2 Axion BioSystems Business Overview
  28. 8.5.3 Axion BioSystems Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Axion BioSystems Immune Mediated Tumor Killing Assays Service Product Portfolio
  30. 8.5.5 Axion BioSystems Recent Developments
  31. 8.6 Sartorius
  32. 8.6.1 Sartorius Company Information
  33. 8.6.2 Sartorius Business Overview
  34. 8.6.3 Sartorius Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sartorius Immune Mediated Tumor Killing Assays Service Product Portfolio
  36. 8.6.5 Sartorius Recent Developments
  37. 8.7 ICE Bioscience
  38. 8.7.1 ICE Bioscience Company Information
  39. 8.7.2 ICE Bioscience Business Overview
  40. 8.7.3 ICE Bioscience Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  41. 8.7.4 ICE Bioscience Immune Mediated Tumor Killing Assays Service Product Portfolio
  42. 8.7.5 ICE Bioscience Recent Developments
  43. 8.8 Shanghai Saily Biotechnology
  44. 8.8.1 Shanghai Saily Biotechnology Company Information
  45. 8.8.2 Shanghai Saily Biotechnology Business Overview
  46. 8.8.3 Shanghai Saily Biotechnology Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Shanghai Saily Biotechnology Immune Mediated Tumor Killing Assays Service Product Portfolio
  48. 8.8.5 Shanghai Saily Biotechnology Recent Developments
  49. 8.9 ProBio
  50. 8.9.1 ProBio Company Information
  51. 8.9.2 ProBio Business Overview
  52. 8.9.3 ProBio Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  53. 8.9.4 ProBio Immune Mediated Tumor Killing Assays Service Product Portfolio
  54. 8.9.5 ProBio Recent Developments
  55. 8.10 Charles River
  56. 8.10.1 Charles River Company Information
  57. 8.10.2 Charles River Business Overview
  58. 8.10.3 Charles River Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Charles River Immune Mediated Tumor Killing Assays Service Product Portfolio
  60. 8.10.5 Charles River Recent Developments
  61. 8.11 Imodels
  62. 8.11.1 Imodels Company Information
  63. 8.11.2 Imodels Business Overview
  64. 8.11.3 Imodels Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Imodels Immune Mediated Tumor Killing Assays Service Product Portfolio
  66. 8.11.5 Imodels Recent Developments
  67. 8.12 Xeno Diagnostics
  68. 8.12.1 Xeno Diagnostics Company Information
  69. 8.12.2 Xeno Diagnostics Business Overview
  70. 8.12.3 Xeno Diagnostics Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Xeno Diagnostics Immune Mediated Tumor Killing Assays Service Product Portfolio
  72. 8.12.5 Xeno Diagnostics Recent Developments
  73. 8.13 Cyagen
  74. 8.13.1 Cyagen Company Information
  75. 8.13.2 Cyagen Business Overview
  76. 8.13.3 Cyagen Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Cyagen Immune Mediated Tumor Killing Assays Service Product Portfolio
  78. 8.13.5 Cyagen Recent Developments
  79. 8.14 MarinBio
  80. 8.14.1 MarinBio Company Information
  81. 8.14.2 MarinBio Business Overview
  82. 8.14.3 MarinBio Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  83. 8.14.4 MarinBio Immune Mediated Tumor Killing Assays Service Product Portfolio
  84. 8.14.5 MarinBio Recent Developments
  85. 8.15 Pharmalegacy
  86. 8.15.1 Pharmalegacy Company Information
  87. 8.15.2 Pharmalegacy Business Overview
  88. 8.15.3 Pharmalegacy Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Pharmalegacy Immune Mediated Tumor Killing Assays Service Product Portfolio
  90. 8.15.5 Pharmalegacy Recent Developments
  91. 8.16 Celentyx
  92. 8.16.1 Celentyx Company Information
  93. 8.16.2 Celentyx Business Overview
  94. 8.16.3 Celentyx Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Celentyx Immune Mediated Tumor Killing Assays Service Product Portfolio
  96. 8.16.5 Celentyx Recent Developments
  97. 8.17 Crown Bioscience
  98. 8.17.1 Crown Bioscience Company Information
  99. 8.17.2 Crown Bioscience Business Overview
  100. 8.17.3 Crown Bioscience Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Crown Bioscience Immune Mediated Tumor Killing Assays Service Product Portfolio
  102. 8.17.5 Crown Bioscience Recent Developments
  103. 8.18 Cellomatics Biosciences
  104. 8.18.1 Cellomatics Biosciences Company Information
  105. 8.18.2 Cellomatics Biosciences Business Overview
  106. 8.18.3 Cellomatics Biosciences Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Cellomatics Biosciences Immune Mediated Tumor Killing Assays Service Product Portfolio
  108. 8.18.5 Cellomatics Biosciences Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst